Results 51 to 60 of about 349 (107)

New anti-obesity medications on the horizon : Exploring the potential of next generation medications

Obesity is a chronic metabolic disease which number is increasing and causing an epidemic problem all around the world. Obesity increases risks for cardiovascular diseases, T2D, non-fatty liver diseases and several types of cancer leading to an increased
Schmitter, Markus
core   +1 more source

Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review. [PDF]

World J Clin Pediatr
Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Dongo-Dueñas LG, Jara-Pianto JMJ, Sierra-Martel JA, Medina-Angulo CA, Virú-Flores HM, Mendoza-Godoy JJ, Zavaleta-Gutiérrez FE, Paz-Ibarra J.   +9 more
europepmc   +1 more source

The 40% weight-reduction craze: market volatility, metabolic nuance, and the quest for sustainable health. [PDF]

Mol Cells
Han W, Shepherd P, Ueki K, Li J, Xu A, Oh G, Kim JB.   +6 more
europepmc   +1 more source

Coadministration of the long‐acting amylin analog cagrilintide plus semaglutide (CagriSema), resulted in significantly greater weight loss, along with improved measures of glucose control, in a short phase 2 trial of patients with type 2 diabetes

Diabetes, Obesity and Metabolism Now, 2023
openaire   +1 more source

Pharmacological management of obesity: Current landscape and emerging therapies. [PDF]

Indian J Pharmacol
Atal S, Agrawal C, Gupta R, Sadasivam B.
europepmc   +1 more source

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. [PDF]

Clin Pharmacokinet
Nielsen MJF, Becker NP, Duus HHH, Kirkeby K, Kupčová V, Lauenborg BW, Low B, Svolgaard O, Witten L.   +8 more
europepmc   +1 more source

A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. [PDF]

Pharmaceuticals (Basel)
Lee S, Song H, Kwon Y.
europepmc   +1 more source

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. [PDF]

Front Endocrinol (Lausanne)
Alhazmi A, le Roux CW.
europepmc   +1 more source

For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better? [PDF]

Biology (Basel)
Giang C, Meng J, Mohammad MA, Liu Z, Wu X, Zhu Y.   +5 more
europepmc   +1 more source

Anti-Obesity Drugs: The Rising Significance of GLP-1Agonist, Tirzepatide. [PDF]

J Midlife Health
Agrawal PK, Garg R.
europepmc   +1 more source